THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Genzyme gets OK to resume testing of MS drug

Patient in trial died of bleeding in the brain

By Stephen Heuser
Globe Staff / May 17, 2007

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

The Food and Drug Administration will allow Genzyme Corp. to continue human tests of a new multiple sclerosis drug that caused a fatal bleeding disease in one trial patient, the company said yesterday. (Full article: 466 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass